David A. Learmonth
David A. Learmonth was born in Glasgow, Scotland, in 1968. He received his B.S. degree in pure chemistry with specialization in biological and medicinal chemistry from the Department of Pure and Applied Chemistry, University of Strathclyde, in 1990, followed by a Ph.D. degree from the same institution in 1994 in research into novel dopamine and serotonin receptor ligands. After gaining experience in the pharmaceutical industry with two multinationals, he joined Laboratórios Bial, Oporto, Portugal, as a Medicinal Chemist in 1994. Since 2001, he has held the position of Head of chemical research within the Department of Research and Development and has the responsibility for drug design, discovery chemistry, analytical chemistry, drug substance manufacturing process research and development, process validation, and elaboration of CMC documentation for worldwide regulatory submissions. He has contributed to the discovery and advancement of ten new chemical entities into the preclinical or late clinical phases of development in humans, including the EU-approved drug Zebinix (eslicarbazepine acetate). His principal areas of scientific interest are central nervous system, cardiovascular and pulmonary disorders, including epilepsy, pain, Parkinson’s disease, hypertension, and asthma. He has authored or coauthored over seventy patents, original research articles, reviews, and book chapters covering biologically active molecules, drug metabolism, drug formulation and administration, polymorphism, and manufacture of intermediates and active drug substances.
Biography Updated on 5 April 2011